2025-07-072025-07-072025El Hammadi, M.M., Martín Navarro, L., Berrocoso, E., Álvarez Fuentes, J., Crespo Facorro, B., Suárez Pereira, I.,...,Martín Banderas, L. (2025). Enhanced Metabolic Syndrome Management Through Cannabidiol-Loaded PLGA Nanoparticles: Development and In Vitro Evaluation. Journal of Biomedical Materials Research Part A, 113 (5), e37916. https://doi.org/10.1002%2Fjbm.a.37916.1549-32961552-4965https://hdl.handle.net/11441/175073Cannabidiol (CBD) holds promise for managing metabolic diseases, yet enhancing its oral bioavailability and efficacy remainschallenging. To address this, we developed polymeric nanoparticles (NPs), using poly(lactic-co-glycolic acid) (PLGA), encapsu-lating CBD using nanoprecipitation, aiming to create an effective CBD-nanoformulation for metabolic disorder treatment. TheseNPs (135–265 nm) demonstrated high encapsulation efficiency (EE% ≈ 100%) and sustained release kinetics. Their therapeuticpotential was evaluated in an in vitro metabolic syndrome model employing sodium palmitate-induced HepG2 cells. Key as-sessment parameters included cell viability (MTT assay), glucose uptake, lipid accumulation (Oil Red O staining), triglycerides,cholesterol, HDL-c levels, and gene expression of metabolic regulators. Results showed an IC50 of 9.85 μg/mL for free CBDapplication/pdf16 p.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AntipsychoticsCannabidiolDiabetesLipid metabolismMetabolic disordersNanomedicineinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.1002%2Fjbm.a.37916